1. BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma
- Author
-
Xianbing, Zhang, Xinyi, Guo, Ran, Zhuo, Yanfang, Tao, Wenxia, Liang, Randong, Yang, Yanling, Chen, Haibo, Cao, Siqi, Jia, Juanjuan, Yu, Xinmei, Liao, Xiaolu, Li, Fang, Fang, Gen, Li, Di, Wu, Yunyun, Xu, Zhiheng, Li, Jian, Pan, and Jian, Wang
- Subjects
N-Myc Proto-Oncogene Protein ,Biophysics ,Nuclear Proteins ,Cell Cycle Proteins ,Dipeptides ,Cell Biology ,Biochemistry ,Gene Expression Regulation, Neoplastic ,Neuroblastoma ,Cell Line, Tumor ,Humans ,Child ,Heterocyclic Compounds, 3-Ring ,Molecular Biology ,Transcription Factors - Abstract
Neuroblastoma(NB) is a common childhood solid tumor, and most patients in the high-risk group with MYCN gene amplification have a poor prognosis. Inhibition of bromodomain and extra terminal (BET) proteins has shown considerable promise in the investigation of MYCN-driven malignancies in recent years. MZ1 is a novel BET inhibitor that employs proteolytic-targeting chimera (PROTAC) technology for proteasomal degradation of target proteins and has shown excellent effects in some tumors, but its role in neuroblastoma remains poorly understood. Herein, we observed that MZ1 suppressed MYC-amplified NB cell proliferation and normal cell cycle, while simultaneously boosting cell apoptosis. MZ1 also provides a significant therapeutic impact in vivo. Mechanistically, MZ1 exhibits anti-tumor effect in NB cells by suppressing the expression of N-Myc or C-Myc as well as the MAPK signaling pathway. Overall, our data imply that MZ1 might be exploited as a possible therapeutic method for NB therapy.
- Published
- 2022